Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Uristat retail recall

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson division McNeil will replace Actavis as manufacturer of its Uristat OTC urinary tract infection tablets after finding problems in Actavis' manufacturing operations. Iceland-based Actavis' U.S. division, Morristown, N.J.-based Actavis Totowa, initiated a retail level recall of Uristat on June 16, McNeil said, adding that no safety problems were reported and the product is not being recalled from consumers. However, because of problems McNeil found in Actavis' manufacturing - concerning "stability indicating methods" used to confirm that a product "performs as intended over its established shelf life" - McNeil said it terminated its contract with the company. McNeil said Uristat will not be available until it hires another manufacturing firm. The Fort Washington, Pa.-based company, which has marketed Uristat since 1996, said it does not have a timetable to return Uristat to market...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101857

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel